Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. (DNPUF) Revenue
Annual & quarterly revenue history · segment & region breakdown
DNPUF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsSumitomo Pharma Co., Ltd. trailing twelve-month (TTM) revenue is $456B, an increase of 14.37% year-over-year from $456B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $456B | +$57.32B | +14.37% |
| 2025-03-31 | $399B | +$84.27B | +26.79% |
| 2024-03-31 | $315B | -$240.99B | -43.38% |
| 2023-03-31 | $556B | -$4.49B | -0.80% |
| 2022-03-31 | $560B | +$44.08B | +8.54% |
| 2021-03-31 | $516B | +$33.22B | +6.88% |
| 2020-03-31 | $483B | +$23.46B | +5.11% |
| 2019-03-31 | $459B | -$7.57B | -1.62% |
| 2018-03-31 | $467B | +$55.19B | +13.41% |
| 2017-03-31 | $412B | +$8.44B | +2.09% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare DNPUF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Sumitomo Pharma Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Sumitomo Pharma Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Sumitomo Pharma Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DNPUF revenue · 4 questionsDNPUF's trailing twelve-month (TTM) revenue is $456B. That is an increase of 14.37% year-over-year from $456B in FY2026.
▸ Source: FMP · Sumitomo Pharma Co., Ltd. SEC filings · GAAP · Sumitomo Pharma Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026